Jose Luis Cuadra-Urteaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jose Luis Cuadra-Urteaga has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Alberto Indacochea
Hospital Universitari Germays Trias I Pujol, Badalona, Barcelona, Spain
5 shared publicationsMaria de Los Llanos Gil
Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain
5 shared publicationsOlatz Etxaniz
Institut Catala d' Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
5 shared publicationsSara Ahlal
Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain
4 shared publications- Carlos Canelo-Aybar
Institut de Recerca Sant Pau (IR Sant Pau) and Centro Cochrane Iberoamericano, Barcelona, Spain (C.C.-A.)
3 shared publications Carmen Balana
Institut Català d'Oncologia Badalona- HU Germans Trias i Pujol, Badalona, Spain
3 shared publications
Latest Publications
- 22 June 2020
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 20 (7) , 653-664
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update
Molecular profiling has led to significantly longer survival in metastatic colorectal cancer (mCRC) patients. Clinical guidelines recommend testing for KRAS/NRAS, BRAF and MSI status, and new biomarkers such as HER2 amplification and NTRK fusions have emerged more recently in refractory CRC, supported by overwhelming clinical relevance. These biomarkers can guide treatment management to improve clinical outcomes in these patients. Preclinical and clinical data over the last decade were reviewed for known and novel biomarkers with clinical implications in refractory CRC. Molecular alterations are described for classic and novel biomarkers, and data for completed and ongoing studies with targeted and immunotherapies are presented. Use of targeted therapies based on biomarker testing in CRC has enabled impressive improvements in clinical outcomes in refractory patients. BRAF, MSI, NRAS and KRAS should be tested upfront in all patients given their indisputable therapeutic implications. Other molecular alterations such as HER2 and NTRK are emerging. Testing for these alterations may further improve outcomes for refractory CRC patients. Nonetheless, many key aspects remain to be defined including the optimal timing and technique for testing, the most adequate panel, and whether all patients should be tested for all alterations.
- 22 June 2020
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 20 (7) , 653-664
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update
Molecular profiling has led to significantly longer survival in metastatic colorectal cancer (mCRC) patients. Clinical guidelines recommend testing for KRAS/NRAS, BRAF and MSI status, and new biomarkers such as HER2 amplification and NTRK fusions have emerged more recently in refractory CRC, supported by overwhelming clinical relevance. These biomarkers can guide treatment management to improve clinical outcomes in these patients. Preclinical and clinical data over the last decade were reviewed for known and novel biomarkers with clinical implications in refractory CRC. Molecular alterations are described for classic and novel biomarkers, and data for completed and ongoing studies with targeted and immunotherapies are presented. Use of targeted therapies based on biomarker testing in CRC has enabled impressive improvements in clinical outcomes in refractory patients. BRAF, MSI, NRAS and KRAS should be tested upfront in all patients given their indisputable therapeutic implications. Other molecular alterations such as HER2 and NTRK are emerging. Testing for these alterations may further improve outcomes for refractory CRC patients. Nonetheless, many key aspects remain to be defined including the optimal timing and technique for testing, the most adequate panel, and whether all patients should be tested for all alterations.
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , 4112
Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.
4112 Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- MEK inhibitor, has been shown to improve outcomes. Prognostic factors in this targeted treated population remain to be studied. Methods: Prospective international cohort of patients who received doublet or triplet anti-BRAF combinations in clinical trials or as compassionate use. Univariate Cox models for OS were constructed and the strongest predictors in stepwise variable selection were used to develop a prognostic score. The final multivariate model with selected predictors was stratified by prior lines. Results: In total, 42 patients were enrolled. Median age 60.7 y (33-83), 61% female, 61% right-sided tumors, 26% received 2 or more prior chemotherapy lines. One patient (2.6%) achieved complete response and 36% had partial response with median follow-up of 14.3 months. Median progression-free survival was 5.5 months (CI95% 4.4-10.4) and median OS (mOS) was 10.7 months (CI95% 8.4-22.1). In univariate models, ECOG performance status (1 vs 0), CEA levels (high - > 3.5 ng/mL- vs low - < 3.5 ng/mL), CA 19.9 (high vs. low), LDH (high vs. low), number of metastatic sites and presence of liver metastasis were significant prognostic factors. On the other hand, MSI status and peritoneal or nodal metastasis did not associate with outcome. In multivariable model, strongest determinants of OS were ECOG and baseline CEA levels. If high-risk for both factors (ECOG 1 and CEA high, 46% of the patients), mOS was 5.6 months (CI95% 4.2-NA); if intermediate-risk (either ECOG 1 or CEA high, 33%), mOS was 13.5 months (CI95% 10.6-NA); if low-risk (ECOG 0 and CEA low, 21%), mOS not reached (CI95% 16.5-NA). Differences between intermediate- and high-risk prognostic groups compared to low-risk were significant (HR = 5.9, p = 0.03; and HR = 25.9, p < 0.001, respectively). Conclusions: Patients characteristics such as ECOG and surrogates of tumor burden like CEA levels remain important OS determinants in BRAF V600 mt mCRC treated with doublet or triplet targeted therapy. In fact, there are not prognostic scores regarding BRAF mt mCRC treated with targeted therapies. Our study suggests that these prognostic factors may be considered as stratification factors in future clinical trials.
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , 4112
Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.
4112 Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- MEK inhibitor, has been shown to improve outcomes. Prognostic factors in this targeted treated population remain to be studied. Methods: Prospective international cohort of patients who received doublet or triplet anti-BRAF combinations in clinical trials or as compassionate use. Univariate Cox models for OS were constructed and the strongest predictors in stepwise variable selection were used to develop a prognostic score. The final multivariate model with selected predictors was stratified by prior lines. Results: In total, 42 patients were enrolled. Median age 60.7 y (33-83), 61% female, 61% right-sided tumors, 26% received 2 or more prior chemotherapy lines. One patient (2.6%) achieved complete response and 36% had partial response with median follow-up of 14.3 months. Median progression-free survival was 5.5 months (CI95% 4.4-10.4) and median OS (mOS) was 10.7 months (CI95% 8.4-22.1). In univariate models, ECOG performance status (1 vs 0), CEA levels (high - > 3.5 ng/mL- vs low - < 3.5 ng/mL), CA 19.9 (high vs. low), LDH (high vs. low), number of metastatic sites and presence of liver metastasis were significant prognostic factors. On the other hand, MSI status and peritoneal or nodal metastasis did not associate with outcome. In multivariable model, strongest determinants of OS were ECOG and baseline CEA levels. If high-risk for both factors (ECOG 1 and CEA high, 46% of the patients), mOS was 5.6 months (CI95% 4.2-NA); if intermediate-risk (either ECOG 1 or CEA high, 33%), mOS was 13.5 months (CI95% 10.6-NA); if low-risk (ECOG 0 and CEA low, 21%), mOS not reached (CI95% 16.5-NA). Differences between intermediate- and high-risk prognostic groups compared to low-risk were significant (HR = 5.9, p = 0.03; and HR = 25.9, p < 0.001, respectively). Conclusions: Patients characteristics such as ECOG and surrogates of tumor burden like CEA levels remain important OS determinants in BRAF V600 mt mCRC treated with doublet or triplet targeted therapy. In fact, there are not prognostic scores regarding BRAF mt mCRC treated with targeted therapies. Our study suggests that these prognostic factors may be considered as stratification factors in future clinical trials.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 12
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mechanisms of resistance have been identified at multiple levels in the epidermal growth factor receptor (EGFR) pathway, including mutations in KRAS, NRAS, and BRAFV600E, and in the HER2 and MET receptors. These alterations represent oncogenic drivers that may co-exist in the same tumor with other primary and acquired alterations via a clonal selection process. Other molecular alterations include DNA damage repair mechanisms and rare kinase fusions, potentially offering a rationale for new therapeutic strategies. In recent years, genomic analysis has been expanded by a more complex study of epigenomic, transcriptomic, and microenvironment features. The Consensus Molecular Subtype (CMS) classification describes four CRC subtypes with distinct biological characteristics that show prognostic and potential predictive value in the clinical setting. Here, we review the panorama of actionable targets in CRC, and the developments in more recent molecular tests, such as liquid biopsy analysis, which are increasingly offering clinicians a means of ensuring optimal tailored treatments for patients with metastatic CRC according to their evolving molecular profile and treatment history.
- 1 January 2020
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 12
Open AccessMolecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mechanisms of resistance have been identified at multiple levels in the epidermal growth factor receptor (EGFR) pathway, including mutations in KRAS, NRAS, and BRAFV600E, and in the HER2 and MET receptors. These alterations represent oncogenic drivers that may co-exist in the same tumor with other primary and acquired alterations via a clonal selection process. Other molecular alterations include DNA damage repair mechanisms and rare kinase fusions, potentially offering a rationale for new therapeutic strategies. In recent years, genomic analysis has been expanded by a more complex study of epigenomic, transcriptomic, and microenvironment features. The Consensus Molecular Subtype (CMS) classification describes four CRC subtypes with distinct biological characteristics that show prognostic and potential predictive value in the clinical setting. Here, we review the panorama of actionable targets in CRC, and the developments in more recent molecular tests, such as liquid biopsy analysis, which are increasingly offering clinicians a means of ensuring optimal tailored treatments for patients with metastatic CRC according to their evolving molecular profile and treatment history.
- 14 November 2018
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 20 (3) , 237-239
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis
Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for treatment of metastatic melanoma in 2011, only two cases of neutrophilic panniculitis in malignancies other than melanoma have been published. Histiocytoid infiltrates of immature neutrophils resembling histiocytes or myelocytes have been reported in Sweet’s syndrome and rarely in other neutrophilic dermatoses. We describe a novel variant of neutrophilic panniculitis with histiocytoid myeloid cells in an early lesion from a patient treated with vemurafenib in combination with an anti-EGFR (epidermal growth factor receptor) agent for metastatic colon carcinoma, three weeks after initiation of therapy. Recognizing this variant of panniculitis associated to BRAFi can avoid misinterpretation of the atypical subcutaneous infiltrate as myeloid leukaemia cutis.
- 14 November 2018
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 20 (3) , 237-239
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis
Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for treatment of metastatic melanoma in 2011, only two cases of neutrophilic panniculitis in malignancies other than melanoma have been published. Histiocytoid infiltrates of immature neutrophils resembling histiocytes or myelocytes have been reported in Sweet’s syndrome and rarely in other neutrophilic dermatoses. We describe a novel variant of neutrophilic panniculitis with histiocytoid myeloid cells in an early lesion from a patient treated with vemurafenib in combination with an anti-EGFR (epidermal growth factor receptor) agent for metastatic colon carcinoma, three weeks after initiation of therapy. Recognizing this variant of panniculitis associated to BRAFi can avoid misinterpretation of the atypical subcutaneous infiltrate as myeloid leukaemia cutis.
- 10 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4577-4586
Outcome prognostic factors in inoperable malignant bowel obstruction
Purpose Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30–40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO. Methods All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8. Results Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p < 0.001 corrected for multiple comparisons). Considering patients alive with persistent obstruction on day 8, a better clinical condition was the variable more associated with desobstruction, but without statistical significance after correction for multiple comparisons. Conclusions A functional physiopathologic mechanism of MBO development may be an early prognostic factor for desobstruction. A high proportion of desobstruction was observed, suggesting that the combination of antisecretories with different mechanism of action warrants further investigation.
- 10 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4577-4586
Outcome prognostic factors in inoperable malignant bowel obstruction
Purpose Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30–40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO. Methods All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8. Results Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p < 0.001 corrected for multiple comparisons). Considering patients alive with persistent obstruction on day 8, a better clinical condition was the variable more associated with desobstruction, but without statistical significance after correction for multiple comparisons. Conclusions A functional physiopathologic mechanism of MBO development may be an early prognostic factor for desobstruction. A high proportion of desobstruction was observed, suggesting that the combination of antisecretories with different mechanism of action warrants further investigation.
- Open Access
- 19 January 2016
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 17 (3) , 233-236
Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component
Carcinosarcomas (CS) are biphasic tumors with malignant epithelial and mesenchymal elements. The sarcomatoid elements of CS can include chondrosarcoma, malignant fibrous histiocytoma, osteosarcoma, leiomyosarcoma, fibrosarcoma, or liposarcoma. CS of the upper urinary tract are extremely rare but are associated with a poor prognosis. We report a case of a 44-year-old man with a localized right renal pelvis mass treated with a right nephroureterectomy. The pathological examination showed a high-grade urothelial carcinoma of the renal pelvis, stage III (pT3aNxM0). A few days later, he developed lower back pain, hematuria, cough with hemoptoic sputum and progressive dyspnea. Radiological explorations showed multiple bilateral lung nodules and a retroperitoneal mass. A CT-guided biopsy of the retroperitoneal mass revealed a high-grade angiosarcoma. A review of the nephrectomy specimen showed a microscopic focus of angiosarcoma in the urothelial carcinoma. Therefore, the initial diagnosis was changed to CS of the renal pelvis with an angiosarcoma component. The patient developed progressive respiratory failure and died 8 weeks after surgery. An autopsy revealed a large retroperitoneal mass with metastatic nodules to the abdominal wall, diaphragm, small intestine, liver, spleen, and lung. All lesions were angiosarcoma, with no evidence of urothelial carcinoma. This is the first case reported of a patient with CS of the upper urinary tract with an angiosarcoma component with a very aggressive course that caused the immediate appearance of multiple angiosarcoma metastases. We also describe the clinical and molecular characteristics of CS, which will help to contribute to a better understanding of this type of tumor.
- 19 January 2016
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 17 (3) , 233-236
Open AccessCarcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component
Carcinosarcomas (CS) are biphasic tumors with malignant epithelial and mesenchymal elements. The sarcomatoid elements of CS can include chondrosarcoma, malignant fibrous histiocytoma, osteosarcoma, leiomyosarcoma, fibrosarcoma, or liposarcoma. CS of the upper urinary tract are extremely rare but are associated with a poor prognosis. We report a case of a 44-year-old man with a localized right renal pelvis mass treated with a right nephroureterectomy. The pathological examination showed a high-grade urothelial carcinoma of the renal pelvis, stage III (pT3aNxM0). A few days later, he developed lower back pain, hematuria, cough with hemoptoic sputum and progressive dyspnea. Radiological explorations showed multiple bilateral lung nodules and a retroperitoneal mass. A CT-guided biopsy of the retroperitoneal mass revealed a high-grade angiosarcoma. A review of the nephrectomy specimen showed a microscopic focus of angiosarcoma in the urothelial carcinoma. Therefore, the initial diagnosis was changed to CS of the renal pelvis with an angiosarcoma component. The patient developed progressive respiratory failure and died 8 weeks after surgery. An autopsy revealed a large retroperitoneal mass with metastatic nodules to the abdominal wall, diaphragm, small intestine, liver, spleen, and lung. All lesions were angiosarcoma, with no evidence of urothelial carcinoma. This is the first case reported of a patient with CS of the upper urinary tract with an angiosarcoma component with a very aggressive course that caused the immediate appearance of multiple angiosarcoma metastases. We also describe the clinical and molecular characteristics of CS, which will help to contribute to a better understanding of this type of tumor.
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e20059
Predictive value of integrative epigenetic profiling in metastatic melanoma (MM) patients (p) treated with BRAF/MEK inhibitors (BMI) and chemotherapy (CT).
E20059 Background: The treatment of MM has evolved over the last four years to include novel treatments in addition to CT, requiring predictive markers of response. Treatment with BMI provides benefit in overall survival, although with early resistance development. The value of CT in these p is limited. Hence, the aim of this work is to perform an integrative epigenetic profiling as predictive tool of resistance to treatment in MM p treated, in one hand with BRAF/MEK inhibitors, and in the other hand, CT-based treatment. The final goal is obtain epigenetic biomarkers to optimize treatment selection and p's outcome. Additionally, we pretend to identify epigenetic biomarkers related to metastatic process. Methods: It was analyzed 35 paraffin-embebbed primary tumor tissue samples from 35 MM p, 20 of them had been treated with BMI and 15 with CT. Additionally, it was analyzed the paired metastasis tissue for a half of them to study the effect of epigenetics in metastatic process. Epigenetic screening was perf...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e20059
Predictive value of integrative epigenetic profiling in metastatic melanoma (MM) patients (p) treated with BRAF/MEK inhibitors (BMI) and chemotherapy (CT).
E20059 Background: The treatment of MM has evolved over the last four years to include novel treatments in addition to CT, requiring predictive markers of response. Treatment with BMI provides benefit in overall survival, although with early resistance development. The value of CT in these p is limited. Hence, the aim of this work is to perform an integrative epigenetic profiling as predictive tool of resistance to treatment in MM p treated, in one hand with BRAF/MEK inhibitors, and in the other hand, CT-based treatment. The final goal is obtain epigenetic biomarkers to optimize treatment selection and p's outcome. Additionally, we pretend to identify epigenetic biomarkers related to metastatic process. Methods: It was analyzed 35 paraffin-embebbed primary tumor tissue samples from 35 MM p, 20 of them had been treated with BMI and 15 with CT. Additionally, it was analyzed the paired metastasis tissue for a half of them to study the effect of epigenetics in metastatic process. Epigenetic screening was perf...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e19112
Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution.
E19112 Background: EGFR-m in NSCLC and its responsiveness to TKI has proved beneficial in a subset of NSCLC patients (p) Breast cancer (BC) represents the most incident neoplasm among women. The co-existence of both EGFR-m-NSCLC and BC has been reported in p with Li-Fraumeni Syndrome. However, no systematic evaluation of the presence of both types of cancers has been performed in the general population. Methods: We sought to evaluate if EGFR-m-NSCLC associates higher rates of 2nd BC than the EGFR-wild type (WT)p. Clinical and molecular characteristics, as well as clinical outcomes of female p visited at our Institution from 2008 to 2014 and harboring both types of tumors were registered. Results: 69/578 female p with EGFR-m were identified. Data on treatment and follow-up of 62p were available. 11/ 62p (17.7%) were diagnosed with both EGFR-m-NSCLC and BC. For EGFR-m-W-p, BC was diagnosed in 3 cases (0.52%) Regarding EGFR-m-NSCLC, age of diagnosis was 65y; 100% of p were Caucasian and never smokers. Del19,...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , e19112
Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution.
E19112 Background: EGFR-m in NSCLC and its responsiveness to TKI has proved beneficial in a subset of NSCLC patients (p) Breast cancer (BC) represents the most incident neoplasm among women. The co-existence of both EGFR-m-NSCLC and BC has been reported in p with Li-Fraumeni Syndrome. However, no systematic evaluation of the presence of both types of cancers has been performed in the general population. Methods: We sought to evaluate if EGFR-m-NSCLC associates higher rates of 2nd BC than the EGFR-wild type (WT)p. Clinical and molecular characteristics, as well as clinical outcomes of female p visited at our Institution from 2008 to 2014 and harboring both types of tumors were registered. Results: 69/578 female p with EGFR-m were identified. Data on treatment and follow-up of 62p were available. 11/ 62p (17.7%) were diagnosed with both EGFR-m-NSCLC and BC. For EGFR-m-W-p, BC was diagnosed in 3 cases (0.52%) Regarding EGFR-m-NSCLC, age of diagnosis was 65y; 100% of p were Caucasian and never smokers. Del19,...
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv501
Second Primary Malignances (Spms) in Patients (P) with Gastrointestinal Stromal Tumors (Gists) – a Coincidence or an Effect of Imatinib?
Aim: GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Imatinib has become the standard treatment for unresectable metastatic GISTs and as adjuvant treatment in high-risk p. A high rate of SPMs (4.5 -33.3%) has been reported in p with sporadic GISTs and a potential association between imatinib treatment and the development of SPMs has been postulated. Methods: We have retrospectively reviewed the incidence of SPMs in all p diagnosed with GIST and treated at a single institution between 1997 and 2012. Results: A total of 95 p were diagnosed with GIST, 21 (22%) of whom developed SPMs. In addition, 18 of the 95 p (18.9%) had premalignant lesions, the most common of which were tubular adenoma (5 p) and melanocytic nevus (4 p). For the 21 p with SPMs, median age at GIST diagnosis was 45.6 years (range, 27-75). The GIST was located in the stomach in 10 p (47.6%) and in the small bowel in 11 (52.4%). The SPMs were in colon (6 p), breast (4 p), kidney (4 p), bladder (3 p), head and neck cancer (3 p), esophagus (2 p), lymphoproliferative disease (2 p), adrenal gland (2 p), skin cancer (1 p), prostate (1 p), pancreas (1 p), bone and soft tissue sarcoma (1 p), pheochromocytoma (1 p), and oligodendroglioma (1 p). 7p had more than one SPM. Only 1 p had been diagnosed with neurofibromatosis as a genetic syndrome. The SPMs were metachronous in 17 p (81%). Only 4 p (19.4%) received imatinib, 2 of whom developed SPMs after treatment. Conclusions: We have observed SPMs in 22% and premalignant lesions in 18.9% of p with GISTs. While the cause of this high rate of SPMs is difficult to determine, it seems that factors other than imatinib treatment may play a role. Further investigation is warranted. Disclosure: All authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv501
Second Primary Malignances (Spms) in Patients (P) with Gastrointestinal Stromal Tumors (Gists) – a Coincidence or an Effect of Imatinib?
Aim: GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Imatinib has become the standard treatment for unresectable metastatic GISTs and as adjuvant treatment in high-risk p. A high rate of SPMs (4.5 -33.3%) has been reported in p with sporadic GISTs and a potential association between imatinib treatment and the development of SPMs has been postulated. Methods: We have retrospectively reviewed the incidence of SPMs in all p diagnosed with GIST and treated at a single institution between 1997 and 2012. Results: A total of 95 p were diagnosed with GIST, 21 (22%) of whom developed SPMs. In addition, 18 of the 95 p (18.9%) had premalignant lesions, the most common of which were tubular adenoma (5 p) and melanocytic nevus (4 p). For the 21 p with SPMs, median age at GIST diagnosis was 45.6 years (range, 27-75). The GIST was located in the stomach in 10 p (47.6%) and in the small bowel in 11 (52.4%). The SPMs were in colon (6 p), breast (4 p), kidney (4 p), bladder (3 p), head and neck cancer (3 p), esophagus (2 p), lymphoproliferative disease (2 p), adrenal gland (2 p), skin cancer (1 p), prostate (1 p), pancreas (1 p), bone and soft tissue sarcoma (1 p), pheochromocytoma (1 p), and oligodendroglioma (1 p). 7p had more than one SPM. Only 1 p had been diagnosed with neurofibromatosis as a genetic syndrome. The SPMs were metachronous in 17 p (81%). Only 4 p (19.4%) received imatinib, 2 of whom developed SPMs after treatment. Conclusions: We have observed SPMs in 22% and premalignant lesions in 18.9% of p with GISTs. While the cause of this high rate of SPMs is difficult to determine, it seems that factors other than imatinib treatment may play a role. Further investigation is warranted. Disclosure: All authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv144
Rechallenge with Bevacizumab (Bev) in Patients (P) with Glioblastoma (Gbm) and Previous Objective Response to Bev
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, iv144
Rechallenge with Bevacizumab (Bev) in Patients (P) with Glioblastoma (Gbm) and Previous Objective Response to Bev